Study identification

PURI

https://redirect.ema.europa.eu/resource/38849

EU PAS number

EUPAS31188

Study ID

38849

Official title and acronym

A Cross-sectional Survey to Evaluate Physician Knowledge of Safety Messages Included in the Physician Education Booklet (PEB) for IMLYGIC®

DARWIN EU® study

No

Study countries

Austria
Germany
Netherlands
United Kingdom

Study description

The overall objective of this study is to evaluate awareness of the IMLYGIC PEB and knowledge of the key messages included in the IMLYGIC PEB among physicians who completed the required IMLYGIC training.

Study status

Finalised
Research institutions and networks

Institutions

Amgen
United States
First published:
21/02/2024
Institution
Multiple centres: 50 centres are involved in the study

Contact details

Global Development Leader Amgen Inc.

Primary lead investigator
Study timelines

Date when funding contract was signed

Planned:
Actual:

Study start date

Planned:
Actual:

Data analysis start date

Planned:
Actual:

Date of final study report

Planned:
Actual:
Sources of funding
Pharmaceutical company and other private sector 

More details on funding

Amgen
Study protocol
Initial protocol
English (6.05 MB - PDF)View document
Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

EU RMP category 3 (required)